(Q36864035)

16 August 2017

1 reference

title

Primer: the fallacy of subgroup analysis (English)

1 reference

16 August 2017

Francis Guillemin

1

1 reference

16 August 2017

publication date

1 July 2007

1 reference

Nature Clinical Practice Rheumatology

16 August 2017

published in

1 reference

16 August 2017

volume

3

1 reference

16 August 2017

issue

7

1 reference

16 August 2017

page(s)

407-413

1 reference

Multiple significance tests: the Bonferroni method

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0528

A consumer's guide to subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0528

Subgroup analysis and covariate adjustment in randomized clinical trials of traumatic brain injury: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0528

7 January 2021

Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0528

7 January 2021

Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0528

7 January 2021

Effect of a high-intensity weight-bearing exercise program on radiologic damage progression of the large joints in subgroups of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0528

7 January 2021

Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0528

7 January 2021

Trials within trials: confirmatory subgroup analyses in controlled clinical experiments

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0528

7 January 2021

Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0528

7 January 2021

Assessing subgroup effects with binary data: can the use of different effect measures lead to different conclusions?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0528

7 January 2021

Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0528

7 January 2021

Multiplicity in randomised trials II: subgroup and interim analyses

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0528

7 January 2021

Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0528

7 January 2021

Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0528

7 January 2021

Stratification of flare intensity identifies placebo responders in a treatment efficacy trial of patients with osteoarthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0528

7 January 2021

Subgroup analysis and other (mis)uses of baseline data in clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0528

7 January 2021

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0528

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0528

1 reference

16 August 2017

1 reference